Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer’s disease development
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective Alzheimer’s disease (AD) is the result of neurodegeneration, which manifests clinically as deficits in memory, thinking, and behavior. It was hypothesized that neuropsychiatric symptoms and the apolipoprotein E genotype increase the likelihood of Alzheimer’s disease development. Methods Utilizing data from the National Alzheimer’s Coordinating Center, information from evaluations of 11,453 cognitively intact participants was analyzed. Survival analysis was used to explore relationships between individual neuropsychiatric symptoms as determined by the Neuropsychiatric Inventory Questionnaire, apolipoprotein E, and eventual AD diagnosis. Cox proportional hazard models were utilized to explore the main effects and synergistic (additive and multiplicative) interactions. Results This study provided evidence for an increased hazard of developing AD among participants with any of the symptoms assessed by the NPI-Q. The hazard of developing AD was almost thirteen times higher for ε4 carriers with delusions and eleven times greater for those with apathy and disinhibition. Statistically significant hazards (p > 0.001) were also realized by ε4 carriers with hallucinations; agitation; depression; anxiety; elation; apathy; irritability; and motor, sleep, and appetite disturbances. Conclusions Findings suggest that neuropsychiatric symptoms are associated with eventual AD diagnosis among a group of cognitively asymptomatic participants at baseline. Many studies begin with a group of participants already impacted by AD diagnosis. The longitudinal analysis of a group of participants who, at baseline, demonstrated no observable signs of AD was a strength of this study. This investigation contributes to the literature exploring an increased hazard of AD due to potential modifiable risk factors and genetic biomarkers such as apolipoprotein E.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
VanderWeele, T. J., & Knol, M. J. (2014) · Epidemiologic Methods · doi:10.1515/em-2013-0005 · Cited by 1,127 · cited 2×
“It is important to note that an additive interaction model is preferred by many epidemiologists with regard to public health risk analysis (VanderWeele & Knol, 2014).”
MethodResultApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876 · cited 1×
“One study found that decreasing APOE e3 and e4 by half in mice led to an increase in b-amyloid clearance in the brain (Jiang et al., 2008).”
BackgroundNeuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378
Protection against Alzheimer's disease with apoE ∈2
Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J., & Goate, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92557-7 · Cited by 225 · cited 1×
“The presence of e2 is considered to be neuroprotective (Talbot et al., 1994).”
BackgroundPeters, M. E., Rosenberg, P. B., Steinberg, M., Norton, M. C., Welsh-Bohmer, K. A., Hayden, K. M., Breitner, J., Tschanz, J. T., & Lyketsos, C. G. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.049 · Cited by 167
Bennett, C., Crawford, F., Osborne, A., Diaz, P., Hoyne, J., Lopez, R., Roques, P., Duara, R., Rossor, M., & Mullan, M. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600102 · Cited by 67
Cited by
Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis
Peters, R., Booth, A., Rockwood, K., Peters, J., D’Este, C., & Anstey, K. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022846 · Cited by 255
Ismail, Z., Gatchel, J., Bateman, D. R., Barcelos-Ferreira, R., Cantillon, M., Jaeger, J., Donovan, N. J., Mortby, M. E., & Mortby, M. E. (2018) · International Psychogeriatrics · doi:10.1017/s1041610217001880 · Cited by 221
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
“[169] analyzed data from the National Alzheimer’s Coordinating Center that included evaluations of 11,453 cognitively intact participants.”
MethodAssociation of anxiety with subcortical amyloidosis in cognitively normal older adults
Hanseeuw, B. J., Jonas, V., Jackson, J., Betensky, R. A., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Donovan, N. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0214-2 · Cited by 61
Metadata
- Authors
- Burke, S. L., Maramaldi, P., Cadet, T., & Kukull, W.
- Venue
- Archives of Gerontology and Geriatrics
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 65
- Pages
- 231-238
- ISSN
- 0167-4943 (ISSN-L)
- OpenAlex
- W2341130468
- Cited by
- 49
- References
- 7
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.